A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Rohey Hydara said that she "condemns" her husband's actions, almost a week after he killed four people.
Tesco faced potential prosecution after admitting overstating its profits in 2014 in an attempt to exaggerate the health of the business.
The female runner almost collapsed towards the end of a half-marathon - but still completed the race with a helping hand or two.